Trials / Completed
CompletedNCT00736489
Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
A Phase II, Double-blind, Placebo-controlled, Randomised, 6-way Cross-over, Single-dose Study to Investigate the Local and Systemic Effects of 3 Doses of Inhaled AZD3199 (a β2-agonist) Compared to Formoterol in Asthmatic Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD3199 | Dry powder for inhalation, single dose |
| DRUG | Formoterol | Dry powder for inhalation, single dose |
| DRUG | Placebo | Dry powder for inhalation, single dose |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-08-18
- Last updated
- 2014-05-19
- Results posted
- 2014-04-03
Locations
4 sites across 2 countries: Denmark, Sweden
Source: ClinicalTrials.gov record NCT00736489. Inclusion in this directory is not an endorsement.